Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma
Open Access
- 28 August 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-11
Abstract
Gradual loss of terminal differentiation markers and gain of stem cell-like properties is a major hall mark of cancer malignant progression. The stem cell pluripotent transcriptional factor SOX family play critical roles in governing tumor plasticity and lineage specification. This study aims to establish a novel SOX signature to monitor the extent of tumor dedifferentiation and predict prognostic significance in hepatocellular carcinoma (HCC). The RNA-seq data from The Cancer Genome Atlas (TCGA) LIHC project were chronologically divided into the training (n = 188) and testing cohort (n = 189). LIRI-JP project from International Cancer Genome Consortium (ICGC) data portal was used as an independent validation cohort (n = 232). Kaplan-Meier and multivariable Cox analyses were used to examine the clinical significance and prognostic value of the signature genes. The SOX gene family members were found to be aberrantly expressed in clinical HCC patients. A five-gene SOX signature with prognostic value was established in the training cohort. The SOX signature genes were found to be closely associated with tumor grade and tumor stage. Liver cancer dedifferentiation markers (AFP, CD133, EPCAM, and KRT19) were found to be progressively increased while hepatocyte terminal differentiation markers (ALB, G6PC, CYP3A4, and HNF4A) were progressively decreased from HCC patients with low SOX signature scores to patients with high SOX signature scores. Kaplan-Meier survival analysis further indicated that the newly established SOX signature could robustly predict patient overall survival in both training, testing, and independent validation cohort. An oncogenic dedifferentiation SOX signature presents a great potential in predicting prognostic significance in HCC, and might provide novel biomarkers for precision oncology further in the clinic.Keywords
Funding Information
- National Natural Science Foundation of China (81702400)
This publication has 42 references indexed in Scilit:
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- The Hedgehog's tale: developing strategies for targeting cancerNature Reviews Cancer, 2011
- A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription ProgramsCell, 2010
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomasNature Genetics, 2009
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular CarcinomaCancer Research, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene listsNucleic Acids Research, 2008
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- The magic of four: induction of pluripotent stem cells from somatic cells by Oct4, Sox2, Myc and Klf4Cell Research, 2007